Guiding treatments for high-risk bladder cancer with biomarkers
Biomarker guided combinations for treating high-risk bladder cancer
This project looks for better ways to combine medicines to treat high-risk bladder cancer, using special markers to guide the choices.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Augusta University NIH-funded |
| Lab location | 1 site (Augusta, United States) |
| Project ID | NIH-11105960 on NIH RePORTER |
What this research studies
Many people with high-grade bladder cancer, especially when it has grown into the bladder wall, face a high risk of the cancer spreading. While surgery is common, and chemotherapy or immunotherapy are used, these treatments don't always stop the cancer from returning or spreading. This project explores new ways to combine existing bladder cancer medicines, like Gemcitabine, by using specific biological markers to help choose the best treatment for each person. Researchers are also exploring a new agent called Chase, which may help overcome resistance to current treatments and improve how well they work.
Who could benefit from this research
Good fit: Patients with high-grade non-muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) who are undergoing or considering treatment would be the focus of this research.
Not a fit: Patients with low-grade bladder cancer or those whose cancer is not responsive to Gemcitabine-based therapies may not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this could lead to more effective and personalized treatment options for patients with high-risk bladder cancer, potentially reducing recurrence and improving survival.
How similar studies have performed: While Gemcitabine-based treatments are currently used, this project explores novel, biomarker-guided combinations and introduces a new agent, Chase, which is a first-of-its-kind approach in humans.
Where this research is happening
Augusta, United States
- Augusta University — Augusta, United States (Active)
Researchers
- Principal investigator: Lokeshwar, Vinata B — Augusta University
- Study coordinator: Lokeshwar, Vinata B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.